TScan Therapeutics, Inc.
NASDAQTCRX arrives at tomorrow's Q1 2026 results having shed more than half its short interest in a month — a sharp retreat that stands out for a micro-cap biotech carrying this much clinical risk. The short-selling pullback is the defining feature of the current setup. Estimated short interest collapsed roughly 51% over the past 30 days to around 940,000 shares, after running near 1.9…
Snapshot as of 22 Jun 2026
TCRX arrives at tomorrow's Q1 2026 results having shed more than half its short interest in a month — a sharp retreat that stands out for a micro-cap biotech carrying this much clinical risk. The short-selling pullback…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TCRX — free to start on ORTEX.
Sign up for free →Open TCRX on ORTEX